Royalty Report: Drugs, Therapeutic, Genome – Collection: 192627

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Therapeutic
  • Genome
  • Disease
  • Cancer
  • Cryogenic
  • Medical
  • Device
  • Diagnostic
  • Test/Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 192627

License Grant
Licensor, government organization, hereby grants and Licensee of the Netherlands accepts a nonexclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products or New Products in the Licensed Fields of Use, to practice and have practiced any Licensed Processes in the Licensed Fields of Use, to make, have made, to use and have used but not to sell any Supplied Materials.  As used in this Agreement, “have made” and “have used” means that Licensee shall have the limited right to use a third party contract manufacturer to make and use only (but not to sell) Supplied Materials, Licensed Products or New Products.  Licensee acknowledges and agrees that any such third party contract manufacturer shall be bound to the terms and obligations of this Agreement.
License Property
Licensed Patent Rights shall mean
(a)  Patent applications (including provisional patent applications and PCT patent applications) or patents listed, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all these patents;
(b)  to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.6(a)
     (i)    continuations-in-part of 2.6(a);
     (ii)   all divisions and continuations of these continuations-in-part;
     (iii)  all patents issuing from these continuations-in-part, divisions, and continuations;
     (iv)  priority patent application(s) of 2.6(a); and
     (v)   any reissues, reexaminations, and extensions of all these patents;
(c) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.6(a) all counterpart foreign and U.S. patent applications and patents to 2.6(a) and 2.6(b), including those listed in Appendix A; and
(d) Licensed Patent Rights shall not include 2.6(b) or 2.6(c) to the extent that they contain one or more claims directed to new matter which is not the subject matter disclosed in 2.6(a).

U.S. Patent Application(s) or Patent(s)
(a)  U.S. Patent Application Serial No. 09/986,618, filed November 9, 2001, now abandoned, entitled “Production of Adeno-Associated Virus in Insect Cells” [HHS Ref. No. E-325-2001/0-US-01];
(b)  U.S. Patent No. 6,723,551, issued April 20, 2004, entitled “Production of Adeno-Associated Virus in Insect Cells” [HHS Ref. No. E-325-2001/1-US-01]; and
(c)  U.S. Patent Application Serial No. 10/415,834, filed May 2, 2003, entitled “Production of Adeno-Associated Virus in Insect Cells” [HHS Ref. No. E-325-2001/2-US-02].

Licensed Products means (a) Supplied Materials and (b) tangible materials, which in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

New Product means a product made using a Licensed Process but excluding Licensed Products.

Licensed Processes means processes, which in the course of being practiced, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

The Disease Lipoprotein Lipase Deficiency
Genetic lipoprotein lipase (LPL) deficiency results in profound hypertriglyceridemia, which is associated with intense chronic abdominal pain, hepatosplenomegaly, eruptive xanthomas, lipemia retinalis, dyspnea, mono- or polyparesthesias, and memory loss. Prolonged elevations in plasma triglycerides (TG) also induce recurrent episodes of often lethal pancreatitis, chronic pancreatic insufficiency, and diabetes mellitus. Currently, no effective treatment for this disease exists. Patients must follow a strict low-fat diet. However, TG levels often remain above the critical threshold. Genetic LPL deficiency type I is a rare, autosomal recessive trait. Prevalence varies between 1 in 1,000,000 in the general population to 1 in 5,000 in French Quebec (a ‘founder effect’).

Acute intermittent porphyria (AlP) is an autosomal dominant inherited condition caused by mutations in the porphobilinogen deaminase (PBGD) gene. The PBGD gene is located on chromosome 11 q24.1 -24.2 and spread over fifteen exons. The protein encoded by this gene is a rate-limiting enzyme, the PBGD enzyme, in the haem synthetic pathway.

Parkinson’s disease (PD) is a progressive neurodegenerative disease, resulting in tremors, stiffness, slowness of movement, and lack of coordination. Patients are faced with a severely debilitating disease and a serious loss in quality of life. PD is caused by degeneration and death of nerve cells in a specific part of the brain known as the substantia nigra. These cells produce dopamine, a substance necessary for communication between nerve cells involved in the coordination of movement.

Field of Use
This agreement pertains to the drug industry relating to the use of the Licensed Patent Rights for the commercial development of AAV related products within the scope of the Agreement.

Licensee is building gene therapies using adeno-associated viral (AAV)-based vectors.

IPSCIO Record ID: 192629

License Grant
Licensor, government organization, hereby grants and Licensee of the Netherlands accepts an exclusive license and non-exclusive license, as specified, under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Licensed Patent Rights shall mean
(a) Patent applications (including provisional patent applications and PCT patent applications) or patents listed, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents;
(b) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.8(a)
    (i)     continuations-in-part of 2.8(a);
    (ii)    all divisions and continuations of these continuations-in-part;
    (iii)   all patents issuing from these continuations-in-part, divisions, and continuations;
    (iv)   priority patent application(s) of 2.8(a); and
    (v)    any reissues, reexaminations, and extensions of these patents;
    (c)    to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.8(a) all counterpart foreign and U.S. patent applications and patents to 2.8(a) and 2.8(b), including those listed; and
    (d)    Licensed Patent Rights shall not include 2.8(b) or 2.8(c) to the extent that they contain one or more claims directed to new matter which is not the subject matter disclosed in 2.8(a).

Patent(s) or Patent Application(s)
1. U. S. Patent 6,984,517, issued January 10, 2006, entitled “AAV5 Vector and Uses Thereof; U.S. Patent 7,479,554, issued January 20, 2009, entitled “AA V5 Nucleic Acids”as well as all issued and pending foreign counterparts [HHS Ref. No. E-127-1998/0];

2. U. S. Patent 6,855,314, issued February 15, 2005, entitled “AAV5 Vector for Transducing Brain Cells and Lung Cells” [HHS Ref. No. E-072-2000/0].

Licensed Products means tangible materials which, in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

Adeno-associated virus (AAV) is a small virus which infects humans and some other primate species.

Field of Use
This agreement pertains to the drug industry.

Exclusive Licensed Field of Use (i) Use of the Licensed Patent Rights for the development and sale of AAV5 based therapeutic products to be delivered to the brain or liver for treatment of human diseases originating in the brain or liver; (ii) Note that arthritis related diseases are expressly excluded.

Non-Exclusive Licensed Field of Use Use of the Licensed Patent Rights for the development and sale of AAV5 based therapeutic products to treat human diseases other than the ones covered under (a)(i).

IPSCIO Record ID: 261354

License Grant
This amendment between the French Licensor and the Licensee of the Netherlands will modify the financial terms associated with royalty payments and create reporting obligations regarding pricing and reimbursement of Licensees gene therapy product Glybera® and its development milestones, and add a Right of First Negotiation for Licensor.  The original agreement was exclusive.
License Property
The original agreement identifies the patents are relating to the preparation and use of recombinant viruses in gene therapy.

The Product shall mean a gene therapy product containing a recombinant virus with a nucleic acid coding for a lipoprotein lipase (LPL) developed, used and/or commercialized by or for Licensee or its affiliates where the activity in relation to such product occurs in one of the countries of the Territory and is covered in whole or in part by a Valid Claim within the Patents in that country.

Field of Use
The Field of Use shall mean indications of Lipoprotein Lipase (LPL) deficiency also referred to as Type I or V hyperlipoproteinernia.

Lipoprotein lipase deficiency (LPLD) is a rare monogenic disorder of triglyceride metabolism. Deficiency of the enzyme lipoprotein lipase results in pronounced accumulation of triglycerides in the plasma. Specifically, the clearance of chylomicrons is impaired. Chylomicrons, fatty droplets that transport fat in the form of triglyceride, appear in the bloodstream shortly after the ingestion of dietary fat. Chylomicrons are normally cleared from the body after a period of fasting. Lipoprotein lipase recognizes a protein in chylomicrons called apolipoprotein C2, and is then activated to metabolize and clear out triglycerides. However, deficiency or lack of lipoprotein lipase results in the accumulation of chylomicrons and triglycerides in the body. High triglyceride levels are present from infancy and childhood, and various associated symptoms may occur. Some patients remain undiagnosed until adulthood. LPLD is caused by mutations in the LPL gene and is inherited in an autosomal recessive manner.

Glybera is used to treat adults with lipoprotein lipase deficiency who have severe or multiple attacks of pancreatitis (inflammation of the pancreas) despite maintaining a low-fat diet.  This is a type of medicine that works by delivering genes into the body.

IPSCIO Record ID: 291109

License Grant
Licensor hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, a nonexclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use set forth in Agreement and to practice and have practiced any Licensed Processes in the Licensed Fields of Use set forth in Agreement and a nonexclusive license under the Licensed Patent Rights and in the Licensed Territory to make and have made, to use and have used, but not to sell and have sold or to offer to sell and to import and Licensed Products in the Licensed Field of Use set forth in Agreement and to practice and have practiced any Licensed Processes in the Licensed Field of Use set forth in Agreement.
License Property
Licensed Products means tangible materials, which in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. Notwithstanding the foregoing, for purposes of calculating Net Sales only Licensed Products shall not include processes which are the subject of a patent application within the Licensed Patent Rights which patent application has been pending in excess of five (5) years from the date it was actually filed and not its effective filing date.

Licensed Patent Rights shall mean (a)  Patent applications and PCT patent applications or patents listed in Agreement, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all these patents; (b)  to the extent that the following contain one or more claims directed to the invention or inventions disclosed; (c)   to the extent that the following contain one or more claims directed to the invention or inventions disclosed in Agreement (a) all counterpart foreign and U.S. patent applications and patents, including those listed in Agreement; and (d)   Subject to the proviso that if the claims in any continuation-in-part as set forth are subject to a terminal disclaimer they would be considered part of the Licensed Patent Rights, to the extent that they contain one or more claims directed to new matter which is not the subject matter disclosed.
5,183,884 – DNA segment encoding a gene for a receptor related to the epidermal growth factor receptor
5,480,968 – Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto
5,820,859 – Method of targeting a therapeutic agent to cells expressing the erb B-3 receptor

Licensed Processes means processes, which in the course of being practiced, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. Notwithstanding the foregoing, for purposes of calculating Net Sales only Licensed Processes shall not include processes which are the subject of a patent application within the Licensed Patent Rights which patent application has been pending in excess of  five  (5) years from the date it was actually filed and not its effective filing date.

Field of Use
Licensed Fields of Use means the fields of use identified below –
(a) Therapeutics Research, development and commercialization of Licensed Products or Licensed Processes for the treatment of erbB-3 related diseases using the Licensed Patent Rights.
(b) Diagnostics; Research, development and commercialization of diagnostic products for the identification, detection and management of disease related to the activity or levels of expression of erbB-3 ('erbB-3 related disease') using the Licensed Patent Rights. For purposes of this Agreement Diagnostics includes prognostic or predictive assays as well as assays used to monitor or select patients for treatment with the Licensed Products or Licensed Processes.
( c) Internal Research Research and development efforts which require the Licensed Patent Rights including drug screening programs where the Licensed Products and Licensed Processes would not be within the Licensed Fields of Use set forth in Paragraphs (a) and.(b) above.

IPSCIO Record ID: 260419

License Grant
The Licensor of France grants to the Licensee of the Netherlands an exclusive license right under the Patents to develop, use, make, have made, sell or offer to sell Product in the Field of Use and in the Territory.
License Property
The patents are relating to the preparation and use of recombinant viruses in gene therapy.

The Product shall mean a gene therapy product containing a recombinant virus with a nucleic acid coding for a lipoprotein lipase (LPL) developed, used and/or commercialized by or for Licensee or its affiliates where the activity in relation to such product occurs in one of the countries of the Territory and is covered in whole or in part by a Valid Claim within the Patents in that country.

Field of Use
The Field of Use shall mean indications of Lipoprotein Lipase (LPL) deficiency also referred to as Type I or V hyperlipoproteinernia.

Lipoprotein lipase deficiency (LPLD) is a rare monogenic disorder of triglyceride metabolism. Deficiency of the enzyme lipoprotein lipase results in pronounced accumulation of triglycerides in the plasma. Specifically, the clearance of chylomicrons is impaired. Chylomicrons, fatty droplets that transport fat in the form of triglyceride, appear in the bloodstream shortly after the ingestion of dietary fat. Chylomicrons are normally cleared from the body after a period of fasting. Lipoprotein lipase recognizes a protein in chylomicrons called apolipoprotein C2, and is then activated to metabolize and clear out triglycerides. However, deficiency or lack of lipoprotein lipase results in the accumulation of chylomicrons and triglycerides in the body. High triglyceride levels are present from infancy and childhood, and various associated symptoms may occur. Some patients remain undiagnosed until adulthood. LPLD is caused by mutations in the LPL gene and is inherited in an autosomal recessive manner.

IPSCIO Record ID: 230758

License Grant
Licensor grants the exclusive license to Licensed Technology and Licensed Patent Rights in the Licensed Territory to develop, to make and have made, to use and have used, and to sell and have sold any Licensed Product in the Licensed Field of Use.
License Property
The Licensed Technology shall mean all Licensor information and data in the Licensed Field of Use that are, or during the term of this Agreement, become available to Licensor and stem from the Clinical Trial for Hemophilia B (Protocol 1998-0-1489) or stem from other clinical trials using adeno-associated virus vectors containing a gene encoding factor IX contemplated or uses adeno-associated virus vector supplied by Licensee.

'Licensed Product{s)' means any product that in the course of manufacture, use, or sale would use the Licensed Technology or, in the absence of this Agreement, infringe one or more claims of the Licensed Patent Rights that have not been held invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

[United States Provisional Patent Application No. 60/040, 711 filed March 14, 1998 entitled 'Methods and Compositions for Use in Gene Therapy for Treatment of Hemophilia' and corresponding United States Patent Application No. 09/038,910 filed March 12,1998] and the International Application No. PCT/US98/04790 filed March 12, 1998.

Field of Use
The technology is for Gene Therapy for Treatment of Hemophilia B.

IPSCIO Record ID: 263765

License Grant
The Licensors of Spain grant to the Licensee of the Netherlands an exclusive right and license, with the right to grant sublicenses, under Licensors interest, right and title in the Joint Patent Rights to use, develop, make, have made and Commercialize Products within the Territory; and,  a non-exclusive, right and license, with the right to grant sublicenses, under the Licensor Background IP required for the use, development, manufacture and/or Commercialization of the Product within the Territory and in the Gene Therapy Field and only to the extent required for said purpose.
License Property
The licensed properties relate to therapies based on constructs including adeno-associated virus (AAV) vectors.

The joint patent rights are for Porphobilinogen deaminase gene therapy.

Field of Use
With this agreement, the Parties modify their collaboration under aforementioned agreements and to refocus their efforts and resources to the further development and commercialization of a gene therapy treatment for acute intermittent porphyria.

The Field of use is Gene Therapy Field for the Disorder of acute intermittent porphyria.  Acute intermittent porphyria (AIP) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.  Porphyria refers to a group of disorders that result from a buildup of natural chemicals that produce porphyrin in your body. Porphyrins are essential for the function of hemoglobin — a protein in your red blood cells that links to porphyrin, binds iron, and carries oxygen to your organs and tissues.

IPSCIO Record ID: 260420

License Grant
Licensor grants to the Licensee of the Netherlands a non-exclusive, non-sublicensable license under the Licensed Patent Rights in each country of the world where there are Valid Claims of Licensed Patent Rights, to make, have made, develop, use, sell, offer to sell and import Licensed Products.
License Property
Licensor has patent rights related to an AAVl Vector gene delivery system.  AAV1 Vector means the adeno-associated virus serotype 1 vector technology which includes without limitation the AAV serotype 1 rep, cap, and ITR sequences and proteins whether utilized in whole or in part to deliver therapeutic genes into cells.
Field of Use
Field means treatment of Lipoprotein Lipase, or LPL, deficiency type 1 and LPL deficiency type 5 by in vivo gene therapy utilizing an AAV 1 Vector encoding the LPL gene.

AMT intends to use the vector for developing therapeutics for treating type I and type V lipoprotein lipase (LPL) deficiency. In particular, AMT will use the vector in the development of its lead gene product, AMT-011, which is in Phase II clinical trials.

Lipoprotein lipase deficiency is a genetic disorder in which a person has a defective gene for lipoprotein lipase, which leads to very high triglycerides, which in turn causes stomach pain and deposits of fat under the skin, and which can lead to problems with the pancreas and liver, which in turn can lead to diabetes.

IPSCIO Record ID: 279313

License Grant
University hereby grants and Licensee hereby accepts an Exclusive license under the Licensed Patents and Licensed Materials to make, have made, import, use, lease, sell and offer for sale and otherwise commercialize and exploit Licensed Products in the Licensed Territory, and practice any method process or procedure within the Licensed Patents in the Licensed Territory.  Said license is Exclusive, including the right to sublicense  in the Licensed Field of Use for a term commencing as of July 1, 1997 and ending on the expiration of the last to expire of the Licensed Patent(s).  University shall have the right to practice the Invention(s) and use the Technology for its own bona fide research, including sponsored research and collaborations. University shall have the right to publish any information included in Licensed Materials and Licensed Patent(s).
License Property
Licensed Product(s) means any product or part thereof in the Licensed Field of Use, the manufacture, use, or sale of which

(a)I s covered by a valid claim of an issued, unexpired Licensed Patent(s) directed to the Invention(s). A claim of an issued, unexpired Licensed Patent(s) shall be presumed to be valid unless and until it has been held to be invalid or unenforceable by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken or is disclaimed, or rejected or found invalid or unenforceable in a reissue application or re- examination proceeding or otherwise;
  
(b) Is covered by any claim being prosecuted in a pending application directed to the Invention(s); or

(c) Incorporates any of the Licensed Materials.

Licensed Patent(s) means any (i) U.S. patent application Serial Number 270,631 filed July 1, 1994 (issued on July 22, 1997 as U.S. Patent Number 5,650,135), (ii) all divisions, substitutions, and continuations in whole or part of any of the preceding, (iii) all foreign patent applications corresponding to or claiming priority from (including International Application Number PCT/US95/15040 and all national applications claiming priority therefrom), and (iv) all U.S. and foreign patents issuing on any of the preceding, including patents of addition, reexaminations, reissues and extensions.

5,650,135 – Non-invasive localization of a light-emitting conjugate in a mammal

Licensed Materials means those biological materials listed, and such other agreed materials as University may provide to Licensee during the term of this Agreement, which shall be added.
– Individual components of light systems (Vectors, genes and gene fragments)
– Bacteria
– Tumor cells
– Indicator cells for HIV
– Transgenic mouse lines

Field of Use
Licensed Field of Use means all uses.

IPSCIO Record ID: 314340

License Grant
University hereby grants to Licensee, who accepts, an exclusive license under the Patent Rights and the Technology in the Field of Use in the Territory, to develop, have developed, to make, have made, to use, have used, to import, have imported, to offer for sale, sell and have sold any Licensed Product. The license granted under this section shall remain in effect throughout the Term and shall be sublicensable by Licensee and/or its Sublicensees through multiple tiers.
License Property
The term Technology means scientific information, knowledge and know-how and materials related to University beta-glucuronidase product candidate for the treatment of MPS VII including, but not limited to data, reports, and materials from preclinical studies, toxicology studies, clinical studies, manufacturing quality, science, and regulatory filings, Betaglucuronidase (GUS) producing cell lines, GUS cell lines, master cell banks, pre-master banks, GUS expression vectors, immune sera to contaminating CHO proteins , or other specific assay reagents created for glucuronidase assays or processes, and access to the mouse MPS VII model for purposes of development of enzyme replacement therapy for MPS VII and other materials related to the development and implementation of the subject matter defined by the Patent Rights.

The term Patent Rights means the patent applications and patents, including all related international filings, reissues, reexaminations, divisions, or continuations thereof and patent applications and any inventions, whether patented or not, which University owns or controls throughout the world, covering or related to the beta-glucuronidase product candidate.

Recombinant human beta-glucuronidase, or rhGUS, is an intravenous, or IV, enzyme replacement therapy for the treatment of mucopolysaccharidosis 7, or MPS 7, also known as Sly Syndrome. Patients with MPS 7 suffer from severe cellular and organ dysfunction that typically leads to death in the teens or early adulthood. MPS 7 is caused by a deficiency of the lysosomal enzyme beta-glucuronidase, which is required for the breakdown of certain complex carbohydrates known as glycosaminoglycans, or GAGs. The inability to properly break down GAGs leads to their accumulation in many tissues, resulting in a serious multi-system disease. There are currently no approved drug therapies for MPS 7.

Field of Use
The term Field of Use means use of the beta-glucuronidase product candidate as a treatment for human disease including MPS VII.

Mucopolysaccharidosis type 7 (MPS 7) is an inherited metabolic disorder. Like other types of MPS disease, MPS 7 is caused by an enzyme deficiency in the processing of glycosaminoglycans (GAGs). In MPS 7, patients lack the enzyme, beta-glucuronidase, which is required for the degradation of the GAGs dermatan sulfate (DS), heparan sulfate (HS), and chondroitin 6 sulfate (CS).

Licensee is a biopharmaceutical company that provides patients products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

IPSCIO Record ID: 262744

License Grant
In the original agreement Licensor granted to the Licensee, of the Netherlands, a non-exclusive sublicense under the Licensed Patent Rights pursuant to the License Agreement, which does not permit further downstream sublicensing.

This amendment adds sublicensing rights.  Licensor grants Licensee of the Neterlands a non-exclusive license under the Licensed Patent Rights in each country of the world where there are Valid Claims of Licensed Patent Rights, to make, develop, use, sell offer to sell, and import Licensed Products, with Restricted Sublicensing Rights.   Restricted Sublicensing Rights means a non-exclusive sublicense under the Licensed Patent Rights from Licensee to sublicensees of Licensee, including Chiesi, pursuant to the sublicensing conditions contained in this Agreement.

License Property
Licensor has exclusively licensed the Licensed Patent Rights relating to an AAVI Vector gene delivery system from a University.

AAV1 Vector means the adeno-associated virus serotype 1 vector technology which includes without limitation the AAV serotype 1 rep, cap, and ITR sequences and proteins whether utilized in whole or in part to deliver therapeutic genes into cells.

Field of Use
Licensee has developed and is commercializing an AAVI product to treat LPL type 1 and LPL type 5 deficiencies.

The original agreement field means treatment of Lipoprotein Lipase, or LPL, deficiency type 1 and LPL deficiency type 5 by in vivo gene therapy utilizing an AAV 1 Vector encoding the LPL gene.

Lipoprotein lipase deficiency is a genetic disorder in which a person has a defective gene for lipoprotein lipase, which leads to very high triglycerides, which in turn causes stomach pain and deposits of fat under the skin, and which can lead to problems with the pancreas and liver, which in turn can lead to diabetes..

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.